Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 48,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Advanced Solid Tumor
Interventions: UCT-01-097, Gemcitabine, Paclitaxel; Drug
Lead sponsor: 1200 Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Los Angeles, California • Torrance, California • Atlanta, Georgia + 3 more

Conditions: Mental Health Wellness 1, Mental Illnesses, Other Diagnoses, Comorbidities, and Complications | Patient
Interventions: Peer whole health intervention, EBPs at Wellness Center; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Cervical Cancer, Genital Warts
Interventions: Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late; Biological
Lead sponsor: Duke University; Other
Eligibility: 9 Years to 18 Years · Female only
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Immunoglobulin A (IgA) Nephropathy
Interventions: Felzartamab, Placebo; Drug · Other
Lead sponsor: HI-Bio, A Biogen Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: Remibrutinib, Ocrelizumab (US); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Arthritis, Reactive, Reiter Disease
Interventions: Doxycycline and Rifampin, Azithromycin and Rifampin, Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Tampa, Florida • New Orleans, Louisiana

Conditions: Gastroesophageal Reflux, Apnea, Bradycardia
Interventions: Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W); Drug · Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Days and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Ketorolac, Joint Fusion
Interventions: great toe (1st metatarsophalangeal joint) fusion, IV Ketorolac, Ketorolac Pill, 5/325mg Oxycodone-Acetaminophen, Aspirin 81Mg Ec Tab; Procedure · Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Subjects
Interventions: PF-06865571, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hodgkin Lymphoma
Interventions: Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
Interventions: Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 7 Days to 30 Days
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Peripheral Arterial Disease
Interventions: Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA); Drug · Behavioral · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cultural Competency, Personal Reflection
Interventions: Visual Arts Immersion; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Spine, Spine Deformity
Interventions: Imaging-Observational; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Autism Spectrum Disorder
Interventions: Autologous Umbilical Cord Blood; Biological
Lead sponsor: Duke University; Other
Eligibility: 24 Months to 72 Months
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Shock, Traumatic
Interventions: 7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more

Conditions: Brain Death, Liver Disease
Interventions: Percutaneous Liver Biopsy; Procedure
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: New Providence, New Jersey • Newark, New Jersey

Conditions: Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
Interventions: bortezomib, gemcitabine hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions: CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine; Device · Procedure · Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: Up to 74 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID19
Interventions: Diagnostic Software as Medical Device; Diagnostic Test
Lead sponsor: AudibleHealth AI, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: pioglitazone; Drug
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Head Lice
Interventions: Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Caries,Dental
Interventions: Self-determination theory; Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 45 Years
Enrollment: 1,268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Anamosa, Iowa • Belle Plaine, Iowa • Cedar Rapids, Iowa + 11 more

Conditions: Overweight and Obesity
Interventions: High sugar/meal feed, High sugar/nibble, High fat/meal feed, High fat/nibble, High sugar/ 3 meals a day, High fat/ 3 meals a day; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 20 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Project Wellness Enhancement: Increasing Health Care Choice and Outcomes for People With Mental Illness

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

Study of Erythromycin in GER-Associated Apnea of the Newborn

Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

Ventilator Pressure and Optimization of Compliance and Hemodynamics

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Impact of Visual Arts Immersion

Evaluating and Establishing the Relationship in the Five Critical X-ray Time Points in Spinal Deformity Realignment

Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)

Hypertonic Resuscitation Following Traumatic Injury

Pre-recovery Bedside Liver Biopsy in Brain Death Organ Donors

Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

Birth to Three - Cavity Free

Dietary Treatment Study of Fat Synthesis and Risk of Cardiovascular Disease